Pricing
  1. JP-listed companies
  2. BrightPath Biotherapeutics Co., Ltd.
  3. Financials
  4. Provision for income taxes

BrightPath Biotherapeutics Co., Ltd. (4594)

Market cap
¥6.3B
P/E ratio
-5.2x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndProvision for income taxes (Million JPY)YoY (%)
Mar 31, 20252+0.00%
Mar 31, 20242+0.00%
Mar 31, 20232-21.49%
Mar 31, 20222+0.00%
Mar 31, 20212-215.96%
Mar 31, 2020-2-155.10%
Mar 31, 20194-26.07%
Mar 31, 20185+1.05%
Mar 31, 20175+241.25%
Mar 31, 20161-62.88%
Mar 31, 20154

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat